home / stock / esaly / esaly quote
Last: | $61.51 |
---|---|
Change Percent: | -1.37% |
Open: | $62.35 |
Close: | $61.51 |
High: | $63.29 |
Low: | $61 |
Volume: | 331,859 |
Last Trade Date Time: | 01/30/2023 03:39:52 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$61.51 | $62.35 | $61.51 | $63.29 | $61 | 331,859 | 01-30-2023 |
$62.835 | $62.29 | $62.835 | $63.35 | $62.29 | 94,525 | 01-27-2023 |
$63.97 | $64.3 | $63.97 | $64.72 | $63.3 | 44,236 | 01-26-2023 |
$64.345 | $64.025 | $64.345 | $64.69 | $63.97 | 44,032 | 01-25-2023 |
$63.5 | $63.52 | $63.5 | $63.82 | $62.44 | 22,761 | 01-24-2023 |
$65.49 | $63.43 | $65.49 | $66 | $63.27 | 12,536 | 01-23-2023 |
$65.95 | $65.385 | $65.95 | $66.19 | $65.385 | 14,592 | 01-20-2023 |
$65.1 | $63.68 | $65.1 | $65.2 | $63.5 | 8,881 | 01-19-2023 |
$64.61 | $64.865 | $64.61 | $64.9 | $64.25 | 6,589 | 01-18-2023 |
$63.92 | $63.04 | $63.92 | $65.03 | $63.04 | 15,353 | 01-17-2023 |
$63.65 | $63.16 | $63.65 | $63.66 | $63.15 | 12,579 | 01-16-2023 |
$63.65 | $63.16 | $63.65 | $63.66 | $63.15 | 12,579 | 01-13-2023 |
$63.15 | $62.92 | $63.15 | $63.15 | $61.85 | 27,532 | 01-12-2023 |
$64.08 | $63.54 | $64.08 | $64.08 | $62.5 | 37,909 | 01-11-2023 |
$65.6 | $65 | $65.6 | $65.6 | $64.772 | 35,042 | 01-10-2023 |
$63.7 | $68 | $63.7 | $68.25 | $63.7 | 70,581 | 01-09-2023 |
$64.2 | $62.96 | $64.2 | $68.85 | $61.07 | 314,515 | 01-06-2023 |
$61.67 | $60.97 | $61.67 | $61.67 | $60.4 | 27,447 | 01-05-2023 |
$62.57 | $63.78 | $62.57 | $63.98 | $62.52 | 22,923 | 01-04-2023 |
$66.35 | $67.004 | $66.35 | $67.004 | $65.96 | 14,469 | 01-03-2023 |
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...